PATENT Attorney Docket No.: 015280-368240US

Client Ref. No.: E-268-1997/2-US-02

## Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

## Listing of Claims:

 (Previously Presented) A method for inducing an antigen specific systemic and rectal mucosal cytotoxic T lymphocyte (CTL) response in a mammalian subject comprising contacting a rectal mucosal tissue of the subject with a composition comprising a chimeric peptide having the amino acid sequence

KOIINMWOEVGKAMYAPPISGOIRRIHIGPGRAFYTTKN (SEO ID NO:9).

## (Canceled)

- (Original) The method of claim 1, wherein said composition further comprises an adjuvant.
- (Previously Presented) The method of claim 3, wherein the adjuvant is cholera toxin (CT), mutant cholera toxin (MCT), or mutant-E. coli heat labile enterotoxin (MLT).
- (Original) The method of claim 1, further comprising administering a purified cytokine to the subject.
- (Previously Presented) The method of claim 5, wherein the cytokine is contacted with a mucosal surface of the subject.
- (Previously Presented) The method of claim 5, wherein the purified cytokine is granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), interleukin-7 (IL-7), interleukin-12 (IL-12) or tumor necrosis factor a (TNFa).

Attorney Docket No.: 015280-368240US Client Ref. No.: E-268-1997/2-US-02

- (Original) The method of claim 1, further comprising administering purified interferon-y to the subject.
- (Original) The method of claim 8, wherein the purified interferon-γ is contacted with a mucosal surface of the subject.
- (Original) The method of claim 5, further comprising administering purified interferon-y to the subject.
- (Original) The method of claim 10, wherein the purified interferon-γ is contacted with a mucosal surface of the subject.
- 12. (Previously Presented) The method of claim 1, wherein said composition further comprises a purified cytokine, wherein the cytokine is granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), interleukin-7 (IL-7), interleukin-12 (IL-12) or tumor necrosis factor α (TNF α).
- (Original) The method of claim 1, wherein said composition further comprises purified interferon-y.
- (Original) The method of claim 12, wherein said composition further comprises purified interferon-γ.

## 15. - 24. (Canceled)

25. (Previously Presented) A method for inducing an antigen specific systemic and rectal mucosal CTL response in a mammalian subject, comprising contacting a rectal mucosal tissue of the subject with a composition comprising a chimeric peptide having the

PATENT Attorney Docket No.: 015280-368240US Client Ref. No.: E-268-1997/2-US-02

amino acid sequence KQIINMWQEVGKAMYAPPISGQIRRIHIGPGRAFYTTKN (SEQ ID NO:9), wherein said composition does not comprise an adjuvant.

- (Original) The method of claim 25, further comprising administering a purified cytokine to the subject.
- 27. (Previously Presented) The method of claim 26, wherein the cytokine is contacted with a mucosal surface of the subject.
- 28. (Previously Presented) The method of claim 27, wherein the purified cytokine is granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), interleukin-7 (IL-7), interleukin-12 (IL-12) or tumor necrosis factor  $\alpha$  (TNF $\alpha$ ).
- 29. (Original) The method of claim 25, further comprising administering purified interferon-γ to the subject.
- 30. (Original) The method of claim 29, wherein the purified interferon- $\gamma$  is contacted with a mucosal surface of the subject.
- (Original) The method of claim 26, further comprising administering purified interferon-y to the subject.
- (Original) The method of claim 31, wherein the purified interferon-γ is contacted with a mucosal surface of the subject.
- 33. (Previously Presented) The method of claim 25, wherein said composition further comprises a purified cytokine; wherein the cytokine is granulocyte-macrophage colonystimulating factor (GM-CSF), interleukin-2 (IL-2), interleukin-7 (IL-7), interleukin-12 (IL-12) or tumor necrosis factor α (TNF α).

Attorney Docket No.: 015280-368240US Client Ref. No.: E-268-1997/2-US-02

34. (Original) The method of claim 25, wherein said composition further comprises purified interferon-y.

- 35. (Original) The method of claim 33, wherein said composition further comprises purified interferon-y.
  - 36. 69. (Canceled)